Trial Search Results

Memantine Augmentation in Obsessive-Compulsive Disorder

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Memantine


Phase 1/Phase 2


Inclusion Criteria:

   - at least 18 years of age

   - suffering from OCD

   - Y-BOCS score of 18 or greater

   - taking a therapeutic dose of an anti-OCD medication specified in the protocol

Exclusion Criteria:

   - diagnosed with a mental disorder other than OCD

   - taking tiagabine or pregabalin

   - having had a previous trial of memantine

   - receiving therapy for OCD

   - substance abuse in the last 6 months

   - personality disorders sufficiently severe to interfere with study participation

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Nona Gamel